Plenvu superior to Moviprep in MORA study for bowel cleansing procedures for colorectal cancer.- Norgine B.V.

Norgine B.V.has announced positive new Plenvu (NER1006) superiority data at the meeting of the Belgian Society for Gastrointestinal Endoscopy (BSGIE). This post hoc analysis of the MORA phase III study, assessed Plenvu cleansing efficacy versus Moviprep in both the overall colon and the right colon, using mean Boston Bowel Preparation Scale (BBPS) Scores. The analysis included 792 patients.

Both Plenvu PM/AM and Plenvu AM/AM attained higher mean overall BBPS scores than Moviprep PM/AM (6.7 and 6.6 versus 6.3; P=0.0001 and P=0.0058 respectively). Similarly in the right colon, both Plenvu PM/AM and Plenvu AM/AM attained significantly higher mean segmental BBPS scores versusMoviprep PM/AM (2.2 and 2.2 versus 2.0; P=0.0003 and P=0.0134). Prof. Raf Bisschops said: �These new data are important. By demonstrating higher cleansing efficacy of the colon compared to the standard 2 litre PEG + Ascorbate bowel preparation, it is clear that Plenvu can help achieve better quality colonoscopy procedure in order to facilitate lesion detection.Plenvu provides a new effective option for healthcare professionals and for patients who may find it easier to comply with a low volume bowel preparation.�

Colonoscopy is a vital screening procedure to detect lesions. Colorectal cancer is the second most common cause of cancer-related mortality in Europe, with over 447,000 new diagnoses every year.